Conference Call with Dr. Lal Pathlabs Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q2FY25 results Revenue increased by 9.8% in Q2FY25, Rs 660 crore compared to Rs 601 crore during Q2FY24. EBITDA increased by 13.9% with a margin of 30.7%. PAT increased by 18.1% with a margin for of 19.8%. Second Interim Dividend of Rs 6 per share for FY25 Result PDF